Home

Results 31 - 40 of 109,409 for susceptible. Search took 1.655 seconds.  
Sort by date/Sort by relevance
For example, when building a dam, it is important to remove all of the organic soil to decrease the possibility of sliding. 10.6 Susceptibility to piping The susceptibility of a soil to piping means the degree of internal erosion which takes place when water moves through the pores or cracks of that soil. (...) The most susceptible materials are fine sands and non- plastic silts with a plasticity index of less than 5. (...) Other soils which have a low susceptibility to piping are the fine-grained, cohesive plastic soils which transmit water very slowly and resist internal erosion well.
Language:English
Score: 805571.4 - https://www.fao.org/fishery/do...ng/General/x6706e/x6706e10.htm
Data Source: un
WHO announces updates on optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex Global Regions WHO Regional websites Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific When autocomplete results are available use up and down arrows to review and enter to select. Select language Select language English العربية 中文 Français Русский Español Português Home Health Topics All topics » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Resources » Fact sheets Facts in pictures Multimedia Publications Questions & answers Tools and toolkits Popular » Air pollution Coronavirus disease (COVID-19) Hepatitis Monkeypox Countries All countries » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Regions » Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific WHO in countries » Statistics Cooperation strategies Ukraine emergency Newsroom All news » News releases Statements Campaigns Commentaries Events Feature stories Speeches Spotlights Newsletters Photo library Media distribution list Headlines » Emergencies Focus on » Afghanistan crisis COVID-19 pandemic Northern Ethiopia crisis Syria crisis Ukraine emergency Monkeypox outbreak Greater Horn of Africa crisis Latest » Disease Outbreak News Travel advice Situation reports Weekly Epidemiological Record WHO in emergencies » Surveillance Research Funding Partners Operations Independent Oversight and Advisory Committee Data Data at WHO » Global Health Estimates Health SDGs Mortality Database Data collections Dashboards » COVID-19 Dashboard Triple Billion Dashboard Health Inequality Monitor Highlights » Global Health Observatory SCORE Insights and visualizations Data collection tools Reports » World Health Statistics 2022 COVID excess deaths DDI IN FOCUS: 2022 About WHO About WHO » People Teams Structure Partnerships and collaboration Collaborating centres Networks, committees and advisory groups Transformation Our Work » General Programme of Work WHO Academy Activities Initiatives Funding » Investment case WHO Foundation Accountability » Audit Budget Financial statements Programme Budget Portal Results Report Governance » World Health Assembly Executive Board Election of Director-General Governing Bodies website Home / News / item / WHO announces updates on optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex WHO announces updates on optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex 12 April 2022 Departmental news Reading time: The broth microdilution plate method represents a promising solution for comprehensive and quality-assured phenotypic drug susceptibility testing in tuberculosis (TB). (...) Subscribe to our newsletters → Related Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex   Regions Africa Americas Eastern Mediterranean Europe South-East Asia Western Pacific Policies Cyber security Ethics Permissions and licensing Preventing sexual exploitation Terms of use About us Careers Library Procurement Publications Frequently asked questions Contact us Subscribe to our newsletters Privacy Legal Notice © 2022 WHO
Language:English
Score: 805571.4 - https://www.who.int/news/item/...bacterium-tuberculosis-complex
Data Source: un
Slide 1 Interrupting LSD virus transmission: Role of vaccines and the evaluation of control programmes Nick Lyons EuFMD/ The Pirbright Institute Lumpy Skin Disease – Vaccination – Online meeting - 7th April 2015 Infected Susceptible INFECTIOUS Diseased Recovered/immune Vaccines and protection TRANSMISSION Infected Susceptible INFECTIOUS Diseased Recovered/immune Vaccines and protection X TRANSMISSION Vaccines may protect against: - Disease Infected Susceptible INFECTIOUS Diseased Recovered/immune Vaccines and protection X Vaccines may protect against: - Disease - Infectiousness X X TRANSMISSION Infected Susceptible INFECTIOUS Diseased Recovered/immune Vaccines and protection X Vaccines may protect against: - Disease - Infectiousness - Infection X TRANSMISSION X X Vaccines and protection Vaccines may protect against Examples: Polio – OPV vs IPV Tuberculosis – BCG FMD – killed vaccines Protective effects are not necessarily absolute….. (...) Vaccine effectiveness – example from Ethiopia Vaccination Yes No Disease Yes 274 (16.2%) 23 (25.0%) No 1413 (83.8%) 69 (75.0%) 1687 92 Incidence in vaccinated = 274/1687 = 16.2% Incidence in unvaccinated = 23/92 = 25.0% Vaccine effectiveness = 1 – (16.2/25.0) = 1 – 0.65 = 0.35 or 35% (95%CI 3-56%) Unpublished data used with permission from Dr Getachew Gari, NAHDIC Vaccine effectiveness – example from Ethiopia Vaccination Yes No Disease Yes 274 (16.2%) 23 (25.0%) No 1413 (83.8%) 69 (75.0%) 1687 92 Incidence in vaccinated = 274/1687 = 16.2% Incidence in unvaccinated = 23/92 = 25.0% Vaccine effectiveness = 1 – (16.2/25.0) = 1 – 0.65 = 0.35 or 35% (95%CI 3-56%) Unpublished data used with permission from Dr Getachew Gari, NAHDIC Vaccine effectiveness will often vary in different settings This estimate is UNADJUSTED for confounders such as age, number of lifetime doses, and previous disease Effectiveness studies – a few key points • Confounders - for observational studies it is essential to adjust for exposure risk and previous disease (i.e. age) • Selection bias – how are areas/farms chosen in the analysis • Ecological studies - Comparing groups or regions is complicated as it is difficult to say all farms are at equal exposure risk…unless this is adjusted for in the analysis • Vaccines doses – should consider the total number of lifetime doses, and the timing of the last dose • Important to consider the impact of maternal immunity Infected Susceptible INFECTIOUS Diseased Recovered/immune Other transmission blocks TRANSMISSION X X X Other control measures: • Clean needles for vaccination/treatment X Infected Susceptible INFECTIOUS Diseased Recovered/immune Other transmission blocks TRANSMISSION X X X Other control measures: • Insecticide?
Language:English
Score: 803861.43 - https://www.fao.org/ag/againfo...ocs/5_LSD_EuFMD_Nick_Lyons.pdf
Data Source: un
WHO | Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update) Global Regions WHO Regional websites Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific When autocomplete results are available use up and down arrows to review and enter to select. عربي 中文 English Français Русский Español Home Health Topics All topics » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Resources » Fact sheets Facts in pictures Multimedia Publications Questions & answers Tools and toolkits Popular » Coronavirus disease (COVID-19) Ebola virus disease Air pollution Hepatitis Top 10 causes of death World Health Assembly » Countries All countries » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Regions » Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific WHO in countries » Statistics Cooperation strategies Democratic Republic of the Congo »   Newsroom All news » News releases Statements Campaigns Commentaries Events Feature stories Speeches Spotlights Newsletters Photo library Media distribution list Headlines » Timeline: WHO's COVID-19 response »   Emergencies Focus on » COVID-19 pandemic Ebola virus disease outbreak DRC 2021 Syria crisis Crisis in Northern Ethiopia Afghanistan Crisis Latest » Disease Outbreak News Travel advice Situation reports Weekly Epidemiological Record WHO in emergencies » Surveillance Research Funding Partners Operations Independent Oversight and Advisory Committee Coronavirus disease outbreak (COVID-19) » WHO © Credits Data Data at WHO » Global Health Estimates Health SDGs Mortality Triple billion targets Data collections Dashboards » COVID-19 Dashboard Triple Billion Dashboard Health Equity monitor Mortality Highlights » GHO SCORE Insights and visualizations Data collection tools Reports World Health Statistics 2021 » WHO © Credits About WHO About WHO » People Teams Structure Partnerships Collaborating Centres Networks, committees and advisory groups Transformation Contact us » Governance » World Health Assembly Executive Board Election of Director-General Governing Bodies website Our Work » General Programme of Work WHO Academy Activities Initiatives Better health for everyone » WHO © Credits Skip to main content Access Home Alt+0 Navigation Alt+1 Content Alt+2 Tuberculosis (TB) Menu Tuberculosis The End TB Strategy Areas of work Detection and diagnosis Early detection Diagnostics Policy Global laboratory initiative Supranational Reference Laboratory Network Active case finding Contact investigation Outbreak management Treatment and care Treatment of drug-resistant TB New drugs Comorbidities Ethical issues Preventive care Latent tuberculosis infection (LTBI) Infection control Vaccines Drug-resistant TB MDR-TB surveillance Treatment of drug-resistant TB Public-private mix for drug-resistant TB TB and HIV Advocacy Research Scale-up Task Force People who use drugs Child and Adolescent TB Addressing needs of vulnerable populations Poverty Refugees Gender Prisons Social determinants People who use drugs Technical support to countries About technical support coordination Partnering with Global Fund Support to countries Technical expertise Community engagement: ENGAGE-TB About ENGAGE-TB Country experiences ENGAGE-TB meetings and events Civil Society Task Force on TB Public-Private Mix Monitoring and evaluation TB data Global Task Force on TB impact measurement MDR-TB surveillance data Financing Digital health Global Task Force on Digital Health for TB TPPs and priority digital health products for TB Research Zoonotic TB TB publications TB data News, events and features About us Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update) Authors : World Health Organization Publication details Publication date : April 2017 Languages : English; French ISBN : ISBN 978-92-4-155000-0 WHO reference number : WHO/HTM/TB/2017.05 Downloads Guidelines for treatment of drug-susceptible tuberculosis and patient care - 2017 update pdf, 500.88 KB Lignes directices pour le traitement de la tuberculose sensible aux médicaments et la prise en charge du patient - Mise à jour 2017 (FR) pdf, 511.63 KB Factsheet - Guidance pdf, 612kb Factsheet (FR) - Guidance pdf, 597kb Factsheet - A patient-centred approach to TB Care Annex 3 - GRADE evidence tables pdf, 761kb Annex 4 - Evidence to decision tables pdf, 606kb Annex 5 - Reports of the systematic reviews pdf, 1.46Mb Annex 6 - Essential first-line antituberculosis drugs pdf, 149kb Overview The WHO Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update) contains policy recommendations on priority areas in the treatment of drug-susceptible TB and patient care. The main highlights of the guidelines are: The category II regimen is no longer recommended for patients who require TB retreatment and drug-susceptibility testing should be conducted to inform the choice of treatment regimen; The use of adjuvant steroids is recommended in the treatment of tuberculous meningitis and pericarditis; Recommendations on the provision of individual or a package of interventions on patient care and support, including patient or staff education, material support, psychological support, and tracers; Recommendations on the use of digital health interventions such as SM or phone call as an tracer option), medication monitor, and video observed treatment (VOT – as a replacement for in-person directly observed treatment - DOT) when conditions of technology and operation allow; Recommendations on the effective treatment administration options: community or home-based DOT, and DOT administered by trained lay providers or health-care workers; and Decentralized model of care is recommended over centralized model for patients on MDR-TB treatment.
Language:English
Score: 803861.43 - https://www.who.int/tb/publica...ns/2017/dstb_guidance_2017/en/
Data Source: un
Résolutions établissant et reconduisant le mandat   Session du CDH Document Titre 42 A/HRC/RES/42/16 (2019) Le droit de toute personne de jouir du meilleur état de santé physique et mentale susceptible d’être atteint 33 A/HRC/RES/33/9 (2016) Le droit de toute personne de jouir du meilleur état de santé physique et mentale susceptible d’être atteint (renouvellement du mandat) 24 A/HRC/RES/24/6 (2013) Le droit de toute personne de jouir du meilleur état de santé physique et mentale susceptible d’être atteint (renouvellement du mandat) 15 A/HRC/RES/15/22 (2010) Le droit de toute personne de jouir du meilleur état de santé physique et mentale susceptible d’être atteint (renouvellement du mandat) 6 A/HRC/RES/6/29 (2007) Le droit de toute personne de jouir du meilleur état de santé physique et mentale susceptible d’être atteint (renouvellement du mandat) Commission Document Titre 61 E/CN.4/RES/2005/24 Le droit de toute personne de jouir du meilleur état de santé physique et mentale susceptible d’être atteint (renouvellement de mandat) 58 E/CN.4/RES/2002/31 Le droit de toute personne de jouir du meilleur état de santé physique et mentale susceptible d’être atteint (établissement du mandat) Résolutions et décisions thématiques ou liées à la santé Session du CDH Document Titre 44 A/HRC/RES/44/33 Rôle central de l'État dans la réponse aux pandémies et autres urgences sanitaires, et leurs conséquences socio-économiques pour faire progresser le développement durable et la réalisation de tous les droits de l'homme (rapport du HCDH) 41 A/HRC/RES/41/10 Accès aux médicaments et aux vaccins (séminaire intersessions et rapport du HCDH) 38 A/HRC/RES/38/8 VIH / sida (table ronde par le HCDH) 36 A/HRC/RES/36/13 Santé mentale (table ronde et rapport du HCDH) 35 A/HRC/RES/35/23 Le droit de toute personne de jouir du meilleur état de santé physique et mentale susceptible d’être atteint dans la mise en œuvre du Programme de développement durable à l'horizon 2030 32 A/HRC/RES/32/18 Santé mentale (rapport du HCDH) 32 A/HRC/RES/32/16 Renforcement des capacités et santé publique (table ronde par le HCDH) 32 A/HRC/RES/32/15 Accès aux médicaments (table ronde par le HCDH) 30 A/HRC/RES/30/8 Contribution du CDH à la réunion de haut niveau sur le VIH / sida en 2016 (rapport du HCDH) 26 A/HRC/RES/26/18 Sport et modes de vie sains comme facteurs contributifs (demande de rapport au Rapporteur spécial) 23 A/HRC/RES/23/14 Accès aux médicaments (résolution générale) 22 A/HRC/RES/22/32 Droit de l'enfant à la santé (rapport du HCDH) 17 A/HRC/RES/17/14 Accès aux médicaments (rapport du Rapporteur spécial) 16 A/HRC/RES/16/28 VIH / SIDA (résolution générale) 12 A/HRC/RES/12/27 VIH / SIDA (étude du SG) 12 A/HRC/RES/12/24 Accès aux médicaments (consultation d'experts par le HCDH) 2 A/HRD/DEC/2/108 Le droit de toute personne de jouir du meilleur état de santé physique et mentale susceptible d’être atteint Commission Document Titre 60 E/CN.4/RES/2004/27 Le droit de toute personne de jouir du meilleur état de santé physique et mentale susceptible d’être atteint (orientation générale) 59 E/CN.4/RES/2003/28 Le droit de toute personne de jouir du meilleur état de santé physique et mentale susceptible d’être atteint (focus on violence) 58 E/CN.4/RES/2002/32 Accès aux médicaments dans le contexte de pandémies telles que le VIH / SIDA 57 E/CN.4/RES/2001/71 Droits de l'homme et bioéthique 57 E/CN.4/RES/2001/33 Accès aux médicaments dans le contexte de pandémies telles que le VIH / SIDA Résolutions de l’Assemblée générale, y compris dans le cadre de l’initiative politique étrangère et santé mondiale Session de l'AG Document Titre 74 A/RES/74/306 Réponse globale et coordonnée à la pandémie de maladie à coronavirus (COVID-19) 73 A/RES/74/132 Santé mondiale et politique étrangère : un monde plus sain grâce à une meilleure nutrition 73 A/RES/73/131 Portée, modalités, format et organisation de la réunion de haut niveau sur la couverture sanitaire universelle 71 A/RES/71/159 Emploi dans la santé et croissance économique 70 A/RES/70/183 Renforcer la gestion des crises sanitaires internationales 69 A/RES/69/132 Protection des agents de santé 68 A/RES/68/98 Liens entre la santé et tous les déterminants, y compris les déterminants sociaux, économiques et environnementaux 67 A/RES/67/81 Protection sociale et mécanismes de financement durable pour la couverture sanitaire universelle 66 A/RES/66/115 Santé et environnement 65 A/RES/65/95 Santé mondiale et politique étrangère 64 A/RES/64/108 Contrôle des maladies infectieuses émergentes et politique étrangère 63 A/RES/63/33 Santé mondiale et politique étrangère 58 A/RES/58/173 Le droit de toute personne de jouir du meilleur état de santé physique et mentale susceptible d’être atteint VOIR CETTE PAGE EN : 中文 English русский Español Mots-clés Santé et handicap Santé mentale Retour en haut Notre action Le Haut-Commissariat des Nations Unies aux droits de l’homme (HCDH) est le principal organisme des Nations Unies dans le domaine des droits de l’homme et a pour mandat unique de promouvoir et de protéger tous les droits de l’homme. © HCDH 1996-2022 À la une Articles d'intérêt Centre des médias Réunions et événements Ressources Bases de données Bibliothèque Publications Se connecter Nous contacter Suivez-nous Travailler avec nous Réseaux sociaux Facebook Twitter Instagram YouTube Faites un don Conditions d'utilisation Contact Données personnelles Droits d'auteur
Language:English
Score: 802862.7 - https://www.ohchr.org/fr/speci...edures/sr-health/about-mandate
Data Source: un
WHONET is a computerized microbiology laboratory data management and analysis program for recording and comparing antimicrobial susceptibility patterns of organisms. WHONET is available in 44 languages, supporting surveillance efforts in over 2,300 hospital, public health, animal health, and food laboratories in over 130 countries worldwide. (...) It aims to explore options for integrating data on antimicrobial susceptibility providing a better knowledge of their antimicrobial susceptibility, therefore contributing to better prescription practices.
Language:English
Score: 802597.46 - https://www.fao.org/vietnam/news/detail-events/en/c/1513567/
Data Source: un
The metabolites are the same in resistant and susceptible crops but their relative distribution depends on the speed and extent of conversion to AMPA. (...) Twelve supervised trials were carried out on glyphosate-susceptible cotton in the USA with pre-harvest application at 3.4 kg ai/ha. (...) Twelve supervised trials on susceptible maize and 66 on resistant maize were carried out in the USA.
Language:English
Score: 802152.93 - https://www.fao.org/3/w8141e/w8141e0u.htm
Data Source: un
Table 1 shows the relative susceptibility of forest stands based on the preferred host composition as a percent of the total basal area. This susceptibility rating will help to determine the relative risk of noticeable defoliation within a given management unit. (...) This option can potentially reduce a management unit’s susceptibility and vulnerability, however trees may still require further protection.
Language:English
Score: 801027.6 - https://www.fao.org/forestry/6...e446122d7431f02449b74a03e5.pdf
Data Source: un
WHONET is a computerized microbiology laboratory data management and analysis program for recording and comparing antimicrobial susceptibility patterns of organisms. WHONET is available in 44 languages, supporting surveillance efforts in over 2,300 hospital, public health, animal health, and food laboratories in over 130 countries worldwide. (...) It aims to explore options for integrating data on antimicrobial susceptibility providing a better knowledge of their antimicrobial susceptibility, therefore contributing to better prescription practices.
Language:English
Score: 799355.03 - https://www.fao.org/vietnam/news/detail-events/zh/c/1513567/
Data Source: un
Assessment of the susceptibility of malaria vectors to insecticides in Guinea-Bissau 2021 | United Nations Development Programme Skip to main content Guinea-Bissau Who we are What we do Our impact Get involved Global Nav toggle Search Who we are What we do Our impact Get involved English Locations Home Guinea-Bissau Assessment of the susceptibility of malaria vectors to insecticides in Guinea-Bissau 2021 Assessment of the susceptibility of malaria vectors to insecticides in Guinea-Bissau 2021 Posted November 9, 2021 Photo: UNDP, 2021 Malaria has been one of the major public health problems in Sub-Saharan African countries and Guinea Bissau is no exception. (...) Field Work:  Between 29 September and 18 October 2021, researchers from the above institution collected samples from 5 regions namely, Bafata, Bissau, Buba, Cacheu and Gabu, to assess the susceptibility of mosquitos to insecticides using World Health Organisation provided kits.
Language:English
Score: 798367.5 - https://www.undp.org/guinea-bi...nsecticides-guinea-bissau-2021
Data Source: un